TrialHuman vaccines & immunotherapeutics2023

Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study.

Miwa Haranaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.